Feature | February 18, 2013

Promus Premier DES Receives European Approval

The next advance in durable polymer stent technology offers easier delivery, flexibility

February 18, 2013 — Boston Scientific received CE mark approval for the Promus Premier everolimus-eluting platinum chromium coronary stent system, the company's next-generation durable polymer drug-eluting stent (DES) technology. The Promus Premier is designed to improve DES performance with a new delivery system and redesigned stent architecture that improves radial, axial strength and deliverability.

The new stent uses the same drug and polymer as the Promus Element, which Boston Scientific said compares very well in trials to the market leading competitor, Abbott’s Xience V. The company said the Promus Premier is being marketed as a workhorse stent.

Coronary heart disease is a narrowing of the vessels that supply blood and oxygen to the heart. Recent statistics from the European Heart Network and the European Society of Cardiology show it is the single most common cause of death in Europe accounting for 1.8 million deaths in Europe per year. Patients living with coronary heart disease, also known as coronary artery disease, may experience pain, shortness of breath and fatigue. They may also be at risk for a heart attack. One treatment option is the placement of a stent in the artery to help keep it open and allow the blood to flow more freely.  

"The customized platinum chromium stent architecture maintains the superior visibility, exceptional radial strength and fracture resistance, minimal recoil and outstanding clinical outcomes of a PtCr everolimus-eluting stent while offering improved longitudinal strength," said John Ormiston, M.D., Mercy Angiography, Auckland City, New Zealand. "In addition, the enhanced stent delivery system offers improved deliverability. Stent design is a balance of trade-offs and the Promus Premier Stent System appears to have it right."

The Promus Premier Stent System was developed with input from physicians. The customized platinum chromium alloy stent architecture provides strength without compromising flexibility. An enhanced low-profile delivery system features a shorter, more visible tip, dual-layer balloon and bi-segment inner lumen catheter designed to facilitate precise stent delivery across challenging lesions. The Everolimus drug and fluorinated co-polymer stent coating have been studied in multiple randomized clinical trials demonstrating long-term safety and efficacy. The Platinum Workhorse Trial compared the Promus Element stent (platinum chromium everolimus-eluting stent) to the Xience V stent (cobalt chromium everolimus-eluting stent), and demonstrated that platinum chromium technology has superior clinical outcomes between years one and two.

The Promus Premier Stent System is currently offered in a matrix of 47 sizes, ranging in diameter from 2.25 to 4 mm and lengths of 8 to 38 mm on a monorail catheter platform. This comprehensive offering provides cardiologists and their patients a broad range of options designed to best suit their needs. The Promus Premier Stent System is not available for sale in the United States or Japan.

For more information: www.bostonscientific.com

Related Content

Interventional cardiology, cath lab technology, TCT, transcatheter cardiovascular therapeutics
Feature | Cath Lab| October 27, 2016 | Dave Fornell
The volume of information attendees receive at the annual Transcatheter Cardiovascular Therapeutics (TCT) interventio
Philips, TCT 2016, image guidance technologies, iFR, HeartNavigator
News | Cath Lab| October 26, 2016
Philips recently announced its latest image guidance solutions to be featured at the 2016 Transcatheter Cardiovascular...
Medtronic, CoreValve Evolut R, TAVR system, 34 mm valve, FDA approval, largest in the U.S.
Technology | Heart Valve Technology| October 26, 2016
Medtronic announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the CoreValve Evolut R 34...
medicare bundled cardiac payments, CMS cardiology payments
Feature | Business| October 24, 2016 | By John W. Meyer, MPH, FACHE
(Editor’s note: This is the second part of a two-part series on the proposed Medicare five-year demonstration for
bioresorbable stents, bioabsorbable stents, visualizing the Absorb BVS, dissolving stent, disappearing stent on IVUS and OCT

A comparison of how the Abbott Absorb BVS appears with intravascular ultrasound (IVUS) on the left, and optical coherence tomography (OCT) of the right. The stent is difficult to visualize and sizing is critical, so both modalities can help in bioresorbable stent measurements and to confirm stent apposition. Left image from the Volcano IVUS system and the right image from St. Jude Medical's OCT system


Feature | Stents Bioresorbable| October 20, 2016 | Dave Fornell
There has been a lot of interest in the interventional community regarding the Abbott Absorb Bioresorbable Vascular S
Avinger, Pantheris atherectomy catheter, OCT, Lumivascular technology, expanded FDA indication, diagnostic imaging device
News | Atherectomy Devices| October 20, 2016
Avinger Inc. recently announced that the company has received expanded indications from the U.S. Food and Drug...
recall, alligator retrieval device, X-Celerator hydrophilic guidewire, UltraFlow flow directed micro catheters, Marathon flow directed micro catheters
News | Cath Lab| October 18, 2016
Medtronic plc announced last week that it has notified customers of a voluntary recall of certain lots of its Pipeline...
Inventory management, Cardinal, RFID inventory tracking, cath lab inventory
Sponsored Content | Whitepapers | Inventory Management| October 18, 2016
As healthcare moves into the era of bundled payments, providers need to be especially focused on ensuring delivery of
angioseal, angio-seal, terumo, St. Jude, vascular closure devices
News | Vascular Closure Devices| October 18, 2016
October 18, 2016 — Abbott and St. Jude Medical Inc.
Overlay Init